CUPERTINO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2007. Total revenues were $6.6 million for the three months ended December 31, 2007, compared to $5.4 million for the same period in 2006. Net loss for the three months ended December 31, 2007 was $7.2 million, compared to a net loss of $9.8 million for the same period in 2006.
For the fiscal year ended December 31, 2007, total revenues were $30.7 million, compared to $21.9 million for the same period in 2006. Net loss for the year ended December 31, 2007 was $24.3 million, compared to a net loss of $33.3 million for the same period in 2006.
At December 31, 2007, DURECT had cash and investments of $62.0 million, compared with cash and investments of $81.6 million at December 31, 2006; these figures include restricted investments of $1.0 million at December 31, 2007 and $1.3 million at December 31, 2006. DURECT's net decrease in cash during 2007 was $19.6 million.
"DURECT's pipeline advanced during 2007, reporting positive clinical
trial results for three programs in Phase III or II. We expect to continue
this progress in 2008 as we look forward to the filing of the first New
Drug Application (NDA) based on our ORADUR(TM) technology and further
advancing our late stage programs," stated James E. Brown, D.V.M.,
President and CEO of DURECT. "Remoxy(TM) met the primary endpoint in its
pivotal Phase III study conducted under a Special Protocol Assessment
(SPA), POSIDUR(TM) reported statistically significant i
|SOURCE DURECT Corporation|
Copyright©2008 PR Newswire.
All rights reserved